Free Trial

Barrow Hanley Mewhinney & Strauss LLC Has $21.50 Million Stock Position in CVS Health Co. (NYSE:CVS)

CVS Health logo with Medical background

Barrow Hanley Mewhinney & Strauss LLC trimmed its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 2.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 479,014 shares of the pharmacy operator's stock after selling 14,304 shares during the period. Barrow Hanley Mewhinney & Strauss LLC's holdings in CVS Health were worth $21,503,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of CVS. Stonebridge Financial Group LLC acquired a new position in CVS Health during the 4th quarter worth $28,000. Hopwood Financial Services Inc. bought a new position in CVS Health in the fourth quarter valued at about $29,000. McIlrath & Eck LLC increased its position in CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares during the period. Financial Perspectives Inc raised its holdings in CVS Health by 137.5% during the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock worth $36,000 after purchasing an additional 466 shares during the last quarter. Finally, Compass Planning Associates Inc acquired a new position in CVS Health during the 4th quarter valued at about $37,000. Institutional investors own 80.66% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on CVS. Royal Bank of Canada increased their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Wolfe Research increased their price target on CVS Health from 67.00 to 70.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Barclays lifted their price objective on CVS Health from $73.00 to $82.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. Leerink Partners upgraded CVS Health from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, Piper Sandler upped their price target on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. Three analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $74.94.

View Our Latest Stock Report on CVS Health

Insider Activity at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.22% of the stock is owned by insiders.

CVS Health Stock Up 0.0%

CVS traded up $0.03 during trading on Thursday, hitting $62.48. The company had a trading volume of 4,132,902 shares, compared to its average volume of 11,265,138. The company has a market capitalization of $79.03 billion, a PE ratio of 17.08, a PEG ratio of 0.98 and a beta of 0.60. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. CVS Health Co. has a one year low of $43.56 and a one year high of $72.51. The firm's 50-day moving average price is $65.76 and its 200 day moving average price is $59.48.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. The company had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 earnings per share. As a group, equities analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.26%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's payout ratio is 63.48%.

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Articles

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Should You Invest $1,000 in CVS Health Right Now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir at All-Time Highs: Take Profits or Hold the Line?
3 Tech Stocks Insiders Are Buying: Speculative Plays for June
3 Defense Stocks Set to Crush the S&P This Summer

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines